Stable micelle and/or liposome compositions and uses thereof

A method for treating conditions of intravascular volume loss in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, and a zeta potential of less than 30 mV.

A method for treating excessive production of nitric oxide in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, and have a zeta potential of less than 30 mV.

A method for increasing the blood pressure in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, and have a zeta potential of less than 30 mV.

A method for treating traumatic brain injury in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method of conducting renal dialysis in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for conducting an exchange transfusion to replace plasma or whole blood that contains harmful mediators, prions, viruses, bacteria, fungi, chemical or biological agents of warfare, cancer cells or other bloodstream born agents in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for diagnosing diseases in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for treating septic shock and irreversible shock in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for conducting Extracorporeal Membrane Oxygenation (ECMO) in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for opening constricted or blocked blood vessels in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for treating dilutional coagulopathy of severe blood loss and bleeding in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for transporting therapeutic gases such as oxygen, nitric oxide, hydrogen sulfide, xenon, argon or carbon monoxide in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.

A method for treating burns in a human or animal subject in need thereof, the method comprising:

• administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising SAMS with an average diameter of from 90 to 120 nm, 102 mM of NaCl, 35 mM of Na (L) lactate, and 10 mM or less of L-histidine,
• wherein the SAMS comprise egg phospholipid in an amount greater than 2% (w/v) of the pharmaceutical composition, wherein the SAMS further comprise a lipid component in an amount of from 20% to 30% (w/v) of the pharmaceutical composition, wherein the lipid component is soybean oil, chia bean oil, algae oil, pumpkin oil, flaxseed oil, fish oil or a combination thereof, and wherein the SAMS have a zeta potential of less than 30 mV.